397 related articles for article (PubMed ID: 36776886)
1. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer/T-cell lymphoma.
Yap DRY; Lim JQ; Huang D; Ong CK; Chan JY
Front Immunol; 2023; 14():1068662. PubMed ID: 36776886
[TBL] [Abstract][Full Text] [Related]
2. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
Vose J; Armitage J; Weisenburger D;
J Clin Oncol; 2008 Sep; 26(25):4124-30. PubMed ID: 18626005
[TBL] [Abstract][Full Text] [Related]
3. Towards Next Generation Biomarkers in Natural Killer/T-Cell Lymphoma.
Chan JY; Lim JQ; Ong CK
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440582
[TBL] [Abstract][Full Text] [Related]
4. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
5. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
Intlekofer AM; Younes A
Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
Rogers AM; Brammer JE
Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma.
Zhang P; Zhang M
Clin Epigenetics; 2020 Nov; 12(1):169. PubMed ID: 33160401
[TBL] [Abstract][Full Text] [Related]
8. Novel target and treatment agents for natural killer/T-cell lymphoma.
Tian XP; Cao Y; Cai J; Zhang YC; Zou QH; Wang JN; Fang Y; Wang JH; Guo SB; Cai QQ
J Hematol Oncol; 2023 Jul; 16(1):78. PubMed ID: 37480137
[TBL] [Abstract][Full Text] [Related]
9. Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.
Huang YH; Qiu YR; Zhang QL; Cai MC; Yu H; Zhang JM; Jiang L; Ji MM; Xu PP; Wang L; Cheng S; Zhao WL
Cell Rep Med; 2024 Feb; 5(2):101416. PubMed ID: 38350451
[TBL] [Abstract][Full Text] [Related]
10. Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy.
Kallam A; Armitage JO
Expert Rev Hematol; 2020 Jul; 13(7):745-753. PubMed ID: 32478625
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the PIK3 pathway in peripheral T-cell lymphoma and NK/T-cell lymphoma.
Huang D; Song TL; Nairismägi ML; Laurensia Y; Pang WL; Zhe DCM; Wong EKY; Wijaya GG; Tan J; Tan SH; Lim JQ; Chia BKH; Chan JY; Tang TPL; Somasundaram N; Cheng CL; Politz O; Liu N; Lim ST; Ong CK
Br J Haematol; 2020 May; 189(4):731-744. PubMed ID: 32004387
[TBL] [Abstract][Full Text] [Related]
12. Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Ekwattanakit S; Khuhapinant A; Chuncharunee S; Niparuck P; Numbenjapon T; Prayongratana K; Kanitsap N; Wongkhantee S; Makruasi N; Wong P; Norasetthada L; Nawarawong W; Sirijerachai C; Chansung K; Suwanban T; Praditsuktavorn P; Intragumtornchai T;
J Geriatr Oncol; 2020 Jan; 11(1):62-68. PubMed ID: 30940492
[TBL] [Abstract][Full Text] [Related]
13. Updating targets for natural killer/T-cell lymphoma immunotherapy.
Xue W; Zhang M
Cancer Biol Med; 2021 Feb; 18(1):52-62. PubMed ID: 33628584
[TBL] [Abstract][Full Text] [Related]
14. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma.
Chang EWY; Tan YH; Chan JY
J Hematol Oncol; 2024 Jun; 17(1):38. PubMed ID: 38824603
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression.
Bennani NN; Kim HJ; Pederson LD; Atherton PJ; Micallef IN; Thanarajasingam G; Nowakowski GS; Witzig T; Feldman AL; Ansell SM
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35750419
[TBL] [Abstract][Full Text] [Related]
16. Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma.
Chen Z; Huang H; Huang H; Yu L; Weng H; Xiao J; Zou L; Zhang H; Liang C; Zhou H; Guo H; Wang Z; Li Z; Wu T; Zhang H; Wu H; Peng Z; Zhai L; Chen X; Liang Y; Hong H; Lin T
Leukemia; 2024 Apr; 38(4):829-839. PubMed ID: 38378844
[TBL] [Abstract][Full Text] [Related]
17. Peripheral T-cell lymphoma - are we making progress?
Khan N; Ozkaya N; Moskowitz A; Dogan A; Horwitz S
Best Pract Res Clin Haematol; 2018 Sep; 31(3):306-314. PubMed ID: 30213401
[TBL] [Abstract][Full Text] [Related]
18. Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
Sugio T; Miyawaki K; Kato K; Sasaki K; Yamada K; Iqbal J; Miyamoto T; Ohshima K; Maeda T; Miyoshi H; Akashi K
Blood Adv; 2018 Sep; 2(17):2242-2252. PubMed ID: 30194138
[TBL] [Abstract][Full Text] [Related]
19. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
20. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
